Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on March 16, 2009

Hypertension. 2009
Published online before print March 16, 2009, doi: 10.1161/HYPERTENSIONAHA.108.128264
A more recent version of this article appeared on May 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
53/5/867    most recent
HYPERTENSIONAHA.108.128264v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moss, N. G.
Right arrow Articles by Goy, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moss, N. G.
Right arrow Articles by Goy, M. F.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*SODIUM
Related Collections
Right arrow Other hypertension

Submitted on December 19, 2008
Revised on January 7, 2009

The Natriuretic Peptide Uroguanylin Elicits Physiologic Actions Through 2 Distinct Topoisomers

Nicholas G. Moss; Dorothy A. Riguera; Robert M. Solinga; Marco M. Kessler; Daniel P. Zimmer; William J. Arendshorst; Mark G. Currie; and Michael F. Goy*

From the Department of Cell and Molecular Physiology (N.G.M., D.A.R., W.J.A., M.F.G.), University of North Carolina, Chapel Hill; and Ironwood Pharmaceuticals (R.M.S., M.M.K., D.P.Z., M.G.C.), Cambridge, Mass.

* To whom correspondence should be addressed. E-mail: mgoy{at}med.unc.edu.

Abstract—The peptide uroguanylin regulates electrolyte transport in the intestine and kidney. Human uroguanylin has 2 conformations that can be stably isolated because of their slow interconversion rate. The A isomer potently activates the guanylate cyclase C receptor found primarily in the intestine. The B isomer, by contrast, is a very weak agonist of this receptor, leading to a widely held assumption that it is physiologically irrelevant. We show here, however, that human uroguanylin B has potent natriuretic activity in the kidney. Interestingly, uroguanylin A and B both induce saluretic responses, but the activity profiles for the 2 peptides differ markedly. The uroguanylin B dose-response curve is sigmoidal with a threshold dose of {approx}10 nmol/kg of body weight, whereas uroguanylin A has a comparable threshold but a bell-shaped dose-response curve. In addition, our study indicates a unique interplay between the A and B isoforms, such that the A form at high concentrations antagonizes the natriuretic action of the B form. These data show that the kidney contains a uroguanylin receptor of which the pharmacological profile does not match that of the well-defined intestinal uroguanylin receptor (guanylate cyclase C), an observation consistent with previous studies showing that the kidney of the guanylate cyclase C knockout mouse remains responsive to uroguanylin. The results presented here also support the unconventional notion that distinct conformations of a single endocrine peptide can elicit different responses in different tissues.


Key words: sodium excretion • natriuretic peptide • hypertension • electrolyte homeostasis • uroguanylin • peptide isomerization